The role of psychedelics in palliative care reconsidered: A case for psilocybin

Abstract

Get full access to this article

View all access options for this article.

References

Bogenschutz

Forcehimes

Pommy

. (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29: 289–299.

Carhart-Harris

Bolstridge

Rucker

. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3: 619–627.

Carhart-Harris

Leech

Hellyer

. (2014) The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 8: 20.

Carhart-Harris

Leech

Williams

. (2012) Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 200: 238–244.

Corlett

Frith

Fletcher

(2009) From drugs to deprivation: a Bayesian framework for understanding models of psychosis. Psychopharmacology (Berl) 206: 515–530.

Corlett

Taylor

Wang

. (2010) Toward a neurobiology of delusions. Prog Neurobiol 92: 345–369.

Friston

(2005) A theory of cortical responses. Philos Trans R Soc Lond B Biol Sci 360: 815–836.

Garcia-Romeu

Griffiths

Johnson

(2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7: 157–164.

Griffiths

Richards

Johnson

. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22: 621–632.

10.

Griffiths

Johnson

Carducci

. (2016) Psilocybin produces substantial and sustained decrease in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30: 1181-1197 .

11.

Griffiths

Johnson

Richards

. (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 218: 649–665.

12.

Griffiths

Richards

McCann

. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187: 268–283; discussion 284–292.

13.

Grob

Bossis

Griffiths

(2013) Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. In Carr

Steel

eds. Psychological Aspects of Cancer. New York: Springer, pp.291–308.

14.

Grob

Danforth

Chopra

. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68: 71–78.

15.

Grof

Goodman

Richards

. (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 8: 129–144.

16.

Johnson

MacLean

Reissig

. (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115: 150–155.

17.

MacLean

Johnson

Griffiths

(2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461.

18.

Ranganathan

Schnakenberg

Skosnik

. (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist Salvinorin A in humans. Biol Psychiatry 72: 871–879.

19.

Ross

Bossis

Guss

. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30: 1165-1180.

20.

Zinberg

(1984) Drug, Set, And Setting: The Basis for Controlled Intoxicant Use. New Haven, CT: Yale University Press.